Sodium oxybate as a potential new treatment for catatonia in patients with depression, Bipolarity or a psychotic disorder, a randomized controlled trial. The Laborit study.
This historical record does not confirm current site availability.
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with bipolarity. Other eligibility criteria apply.
- Listed locations
- Netherlands and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This is historical registry information. What is the current study status and protocol?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Amsterdam UMC
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Netherlands
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2021-004049-19
- Official title
Show the full official title
Sodium oxybate as a potential new treatment for catatonia in patients with depression, bipolar disorder or a psychotic disorder, a randomized controlled trial. The Laborit study.
Recruitment & locations
Antes — psychiatry · Amsterdam · Hilversum
1 more locations
- Leiden
Registry details
Original registry record (opens in a new tab)- Netherlands — Ongoing, recruiting
- Netherlands — Trial now transitioned
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Amsterdam UMC.
Who can participate?
This study is for people with bipolarity. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
